{
  "nctId": "NCT04252170",
  "briefTitle": "Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly",
  "officialTitle": "Arm Motor Rehabilitation, Entertainment and Cognition System for the Elderly (Feasibility Study)",
  "protocolDocument": {
    "nctId": "NCT04252170",
    "filename": "Prot_001.pdf",
    "label": "Study Protocol",
    "date": "2018-08-24",
    "uploadDate": "2020-01-22T11:50",
    "size": 716456,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04252170/document/Prot_001.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 2,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-09-15",
    "completionDate": "2019-01-31",
    "primaryCompletionDate": "2018-12-31",
    "firstSubmitDate": "2020-01-22",
    "firstPostDate": "2020-02-05"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Age 50 to 85;\n* diagnosis of first-time CVA that occurred more than 5 days prior and less than 21 days prior\n* English speakers;\n* UE unilateral or bilateral involvement (from new bilateral CVA)\n* motor involvement (FMA score 20 to 45);\n* ability to actively move UE more than 10 degrees for shoulder and elbow flexion/extension;\n* ability to actively extend fingers at least 5 degrees\n* cognitive skills to participate (Montreal Cognitive Assessment (MoCA) \\[Nasreddine et al 2005\\] score 10-30).\n* Subjects may have normal cognition, MCI or dementia\n\nExclusion Criteria:\n\n* being younger than 50 or older than 85 years of age\n* previous stroke\n* Stroke that occurred more than 20 days prior to enrollment\n* Inability to actively extend fingers at least 5 degrees;\n* Fugl-Meyer scores of 19 or less;\n* severe visual neglect or legally blind\n* severe hearing loss or deafness\n* receptive aphasia or severe expressive aphasia;\n* severe spasticity (Modified Ashworth Scale 4/4)\n* contractures of the upper limb joints\n* uncontrolled hypertension (\\>190/100 mmHg)\n* severe cognitive impairment determined by Montreal Cognitive Assessment (MoCA) \\[Nasreddine et al, 2005\\] test of 9 and below;\n* No chemodenervation or nerve block to upper limb involved during the experimental period (e.g., botulinum toxin injection)\n* inability to speak English;\n* a history of violence or drug abuse;\n* paranoia and psychotic behavior;\n* inability participate in the neuropsychological pre-study assessment for reliable scores (e.g., cognitive impairment, communication disorders).",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "50 Years",
    "maximumAge": "85 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Artificial Intelligence-determined game difficulty level",
        "description": "BrightBrainer game difficulty setting is determined based on patient's past performance, in order to adapt the therapy to a given individual. It representing an average or difficulties of all games played in a session. The measure implies game play intensity and level of challenge",
        "timeFrame": "Through study completion, an average of 3 weeks"
      },
      {
        "measure": "Game Score (baseline and performance)",
        "description": "BrightBrainer game baseline and performance scores. Min. score is 0. Max depends on specific game.",
        "timeFrame": "Through study completion, an average of 3 weeks"
      },
      {
        "measure": "Participants' feedback using 5-point Likert scale",
        "description": "Subjective evaluation feedback and overall ratings on BrightBrainer games. Consists of multiple questions, each ranked on a 5-point Likert scale, with 1 (min) and 5 (max).",
        "timeFrame": "Through study completion, an average of 3 weeks"
      },
      {
        "measure": "Therapist subjective evaluation using 5-point Likert scale",
        "description": "Subjective evaluation given by the attending Occupational Therapist at the end of the experimental intervention. Multiple questions, each ranked from 1 (min) to 5 (max)",
        "timeFrame": "3 weeks"
      }
    ],
    "secondary": [
      {
        "measure": "Arm Range of Motion",
        "description": "measurement of active movement initiated by participant using a mechanical goniometer",
        "timeFrame": "Change from Baseline arm range of motion at 3 weeks"
      },
      {
        "measure": "Finger Range of Motion",
        "description": "finger extension/flexion range using a mechanical goniomter",
        "timeFrame": "Change from Baseline finger range of motion at 3 weeks"
      },
      {
        "measure": "Grasp Strength with Jamar Dynamo-meter",
        "description": "grasp strength measurement using dynamo-meter",
        "timeFrame": "Change from Baseline grasp strength at 3 weeks"
      },
      {
        "measure": "Pinch strength with pinch meter",
        "description": "Pinch strength measured with fingers placed on a pinch meter",
        "timeFrame": "Change from Baseline at 3 weeks"
      },
      {
        "measure": "Shoulder strength",
        "description": "Measurement of shoulder strength using calibrated wrist weights",
        "timeFrame": "Change from Baseline shoulder strength at 3 weeks"
      },
      {
        "measure": "Fugl-Meyer Assessment (Upper Extremity sub-scale) score",
        "description": "Upper Extremity Motor function, score scale is 0 (min) to 66 (max). Larger score means better outcome.",
        "timeFrame": "Change from Baseline Fugl-Meyer Assessment Score at 3 weeks"
      },
      {
        "measure": "Upper extremity functional index (UEFI) score",
        "description": "A self report of independence in 20 activities of daily living (ADLs). Total score range is 0 (min) to 80 (max). Larger score means better outcome.",
        "timeFrame": "Change from Baseline Upper Extremity Functional Inex score at 3 weeks"
      },
      {
        "measure": "CAHAI 9 Score",
        "description": "Chedoke Arm and Hand Activity Inventory, reflecting ADL independence in simulated bimanual activities. Min score 9, max score 63, with larger score meaning better outcomes.",
        "timeFrame": "Change from Baseline CAHAI 9 score at 3 weeks"
      },
      {
        "measure": "Jebsen Test of Hand Function",
        "description": "Timed test of 7 simulated activities of daily living. Lowest score is 0, largest score is 1260. Units are seconds. Lower score means better outcomes (faster completion).",
        "timeFrame": "Change from Baseline Jebsen Test of Hand Function score at 3 weeks"
      },
      {
        "measure": "Beck Depression Inventory II (BDI II) score",
        "description": "participants' depression measure. Range is 0 (min) to 63 (max). Lower score indicate better outcomes (less depression).",
        "timeFrame": "Change from Baseline depression severity at 3 weeks"
      },
      {
        "measure": "Verbal attention",
        "description": "Attention module digit span (working memory) in the Neuropsychological Assessment Battery NAB min 0, larger score is better",
        "timeFrame": "Change from Baseline verbal attention at 3 weeks"
      },
      {
        "measure": "Verbal fluency",
        "description": "verbal fluency test min 0, larger score is better",
        "timeFrame": "Change from Baseline verbal fluency at 3 weeks"
      },
      {
        "measure": "Verbal memory",
        "description": "Hopkins Verbal Learning Test, Revised (HVLT-R) min 0, larger is better",
        "timeFrame": "Change from Baseline verbal learning memory at 3 weeks"
      },
      {
        "measure": "Brief Visuospatial Memory Test-Revised",
        "description": "A measure of memory function min 50 std of 10, larger score is better",
        "timeFrame": "Change from Baseline visuospatial memory at 3 weeks"
      },
      {
        "measure": "Executive Function Module",
        "description": "Word Generation min 0, larger is better",
        "timeFrame": "Change from Baseline executive function at 3 weeks"
      },
      {
        "measure": "Cognitive executive function",
        "description": "Trail Making Test B (TMT-B) lMin 50, std of 10, larger number means better outcomes",
        "timeFrame": "Change from Baseline Trail Making Test B (TMT-B) Score at 3 weeks"
      },
      {
        "measure": "Cognitive executive function",
        "description": "NAB Executive Functioning Module min 50, std is 10, larger number means better outcomes",
        "timeFrame": "Change from Baseline NAB Exec Score at 3 weeks"
      },
      {
        "measure": "Visual attention",
        "description": "Attention module dots (visual) in the Neuropsychological Assessment Battery NAB",
        "timeFrame": "Change from Baseline visual attention at 3 weeks"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 4,
      "secondaryCount": 18,
      "otherCount": 0,
      "totalCount": 22
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-21T22:34:13.360Z",
  "dataSource": "ClinicalTrials.gov API v2 - Mass Collection"
}